Cargando…

Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis

Previous trial evidence suggested potential risk of serious urinary tract infections (UTIs) and genital infections in type 2 diabetes patients using sodium glucose co-transporter-2 inhibitors (SGLT2) inhibitors. We conducted a systematic review and meta-analysis to assess the effects of SGLT2 inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Jiali, Li, Ling, Li, Sheyu, Jia, Pengli, Deng, Ke, Chen, Wenwen, Sun, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460243/ https://www.ncbi.nlm.nih.gov/pubmed/28588220 http://dx.doi.org/10.1038/s41598-017-02733-w

Ejemplares similares

Effect of SGLT2 Inhibitors on Type 2 Diabetes Mellitus With Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
por: Wei, Qiong, et al.
Publicado: (2021)

The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients
por: Tilinca, Mariana Cornelia, et al.
Publicado: (2021)

Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation
por: McGovern, Andrew P, et al.
Publicado: (2020)

Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus
por: Kaushal, Shaveta, et al.
Publicado: (2014)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and Genital Infections in Patients With Diabetic Mellitus and Concomitant Coronary Artery Disease: A Single-Center Experience
por: Shah, Bhupesh R, et al.
Publicado: (2022)

Use of SGLT-2 Inhibitors in Patients With Type 1 Diabetes Mellitus
por: El Hage, Lea, et al.
Publicado: (2020)

Can SGLT2 Inhibitor be Used for Diabetes Mellitus or Vascular Diseases?
por: Nomiyama, Takashi
Publicado: (2020)

Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus
por: Suzuki, Yuta, et al.
Publicado: (2022)

Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis
por: Liu, Jiali, et al.
Publicado: (2017)

A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor
por: Jung, Chang Hee, et al.
Publicado: (2014)

Risk of genital and urinary tract infections associated with SGLT‐2 inhibitors as an add‐on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea
por: Yang, Hyeri, et al.
Publicado: (2022)

A literature review and meta-analysis of safety profiles of SGLT2 inhibitors in Japanese patients with diabetes mellitus
por: Mukai, Junichi, et al.
Publicado: (2021)

The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 Inhibitors and Pioglitazone
por: Li, Yan-Rong, et al.
Publicado: (2021)

Efficacy of Body Weight Reduction on the SGLT2 Inhibitor in People with Type 2 Diabetes Mellitus
por: Cho, Hyun A, et al.
Publicado: (2017)

SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failure—A Concise Review
por: Keller, Daria M., et al.
Publicado: (2022)

SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis
por: Shyangdan, Deepson S, et al.
Publicado: (2016)

Diabetes Mellitus and Heart Failure: Epidemiology, Pathophysiologic Mechanisms, and the Role of SGLT2 Inhibitors
por: Theofilis, Panagiotis, et al.
Publicado: (2023)

Urinary tract infections (UTIs) or genital tract infections (GTIs)? It's the diagnostics that count
por: Behzadi, Payam, et al.
Publicado: (2019)

Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors
por: Fadini, Gian Paolo, et al.
Publicado: (2019)

The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review
por: McGill, Janet B.
Publicado: (2014)

Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
por: Fioretto, Paola, et al.
Publicado: (2015)

Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure
por: Pradhan, Akshyaya, et al.
Publicado: (2019)

Effectiveness and Safety of SGLT2 Inhibitors in Clinical Routine Treatment of Patients with Diabetes Mellitus Type 2
por: Hopf, Maximilian, et al.
Publicado: (2021)

Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus
por: Sim, A Young, et al.
Publicado: (2021)

Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis
por: Castellana, Marco, et al.
Publicado: (2019)

Comparative Cardiovascular Outcomes of SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Network Meta-Analysis of Randomized Controlled Trials
por: Jiang, Yu, et al.
Publicado: (2022)

Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials
por: Pan, Runzhou, et al.
Publicado: (2022)

Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies
por: Li, Chun Xing, et al.
Publicado: (2023)

Benefits of SGLT2 inhibitors in arrhythmias
por: Gao, Jinghan, et al.
Publicado: (2022)

Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors
por: Qiu, Mei, et al.
Publicado: (2021)

SGLT-2 inhibitors and their potential in the treatment of diabetes
por: Rosenwasser, Rebecca F, et al.
Publicado: (2013)

Euglycemic Diabetic Ketoacidosis With SGLT-2 Inhibitor
por: Manas, F N U, et al.
Publicado: (2021)

SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials
por: Li, Wen-jie, et al.
Publicado: (2020)

The Efficacy and Safety of the Combination Therapy With GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
por: Li, Chen, et al.
Publicado: (2022)

Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus
por: Mirabelli, Maria, et al.
Publicado: (2019)

Association of SGLT2 inhibitors with lower incidence of death in type 2 diabetes mellitus and causes of death analysis
por: Chung, Mu-Chi, et al.
Publicado: (2022)

Copeptin adaptive response to SGLT2 inhibitors in patients with type 2 diabetes mellitus: The GliRACo study
por: Berton, Alessandro Maria, et al.
Publicado: (2023)

Changes in Cardiovascular and Renal Biomarkers Associated with SGLT2 Inhibitors Treatment in Patients with Type 2 Diabetes Mellitus
por: Peppa, Melpomeni, et al.
Publicado: (2023)

Effect of Sodium Glucose Cotransporter 2 Inhibitors With Low SGLT2/SGLT1 Selectivity on Circulating Glucagon-Like Peptide 1 Levels in Type 2 Diabetes Mellitus
por: Takebayashi, Kohzo, et al.
Publicado: (2017)

Are SGLT2 polymorphisms linked to diabetes mellitus and cardiovascular disease? Prospective study and meta-analysis
por: Drexel, Heinz, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fr09ghj4uggviohffd0u2uhv5g